Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-A1921 + adebrelimab + SHR-8068 + carboplatin
- Development stage
- Preclinical
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A combination regimen comprised of four agents: - **SHR-A1921**, an antibody-drug conjugate (ADC) under investigation for solid tumors including platinum-resistant ovarian cancer and triple-negative breast cancer with brain metastasis. - **Adebrelimab**, a fully humanized monoclonal antibody targeting programmed cell death ligand 1 (PD-L1), approved in China in combination with chemotherapy for extensive-stage small cell lung cancer, and broadly studied for its immunotherapy anticancer effects. - **SHR-8068**, for which public specific details are extremely limited; based on pharmaceutical code naming, SHR-8068 is presumed to be an investigational agent, likely a novel immune modulator or targeted therapy developed by Hengrui. - **Carboplatin**, a well-established small molecule platinum-based DNA-damaging chemotherapy. The combination leverages cytotoxicity (carboplatin), tumor targeting (SHR-A1921 ADC), and immunotherapy (adebrelimab, potentially SHR-8068). The regimen is proposed in cancer clinical trials for diseases such as ovarian cancer and small cell lung cancer.
- Other names
- SHR-A1921 + adebrelimab + SHR-8068 + carboplatin
02
Targets
TACSTD2 (Tumor-associated calcium signal transducer 2)TOP1 (DNA Topoisomerase I)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)CD274 (Programmed cell death protein 1 ligand 1)DNA
Beyond the preview
Go deeper on SHR-A1921 + adebrelimab + SHR-8068 + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-A1921 + adebrelimab + SHR-8068 + carboplatin.